Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

January 17, 2019

Erleada Approved in Europe for Castration-resistant Prostate Cancer Patients at High Risk of Metastasis

News

The European Commission has approved the use of Erleada (apalutamide) for the treatment of men with castration-resistant prostate cancer at high risk of developing metastasis, announced Janssen Oncology, the therapy’s developer. The ... Read more

January 7, 2019

Phase 2 Trial Assessing CPI-1205, Plus Xtandi, Begins Dosing Metastatic CRPC Patients

News

Constellation Pharmaceuticals has begun patient dosing in the second part of a Phase 1b/2 trial testing its investigational inhibitor CPI-1205, in combination with Xtandi (enzalutamide), for the second-line treatment of ... Read more

January 3, 2019

Trial Studies Gold Nanoparticles as Way to Eliminate Localized Prostate Cancer

News

A new approach that uses light-activated gold nanoparticles is being tested in a small clinical trial as a way to eliminate prostate cancer in patients with localized tumors. The ... Read more

December 13, 2018

10-Year Survival of Young Low- and Intermediate-risk Prostate Cancer Patients Better with Radiation than Surgery

News

Radiation therapy approaches — including brachytherapy and external beam radiation therapy (EBRT) — lead to better 10-year survival rates than prostate surgery in young patients with low- and intermediate-risk ... Read more

December 5, 2018

ADT Increases Risk for Fractures in Older Prostate Cancer Patients, Study Shows

News

Elderly prostate cancer patients taking androgen deprivation therapy (ADT) have an increased risk for bone fractures compared to prostate cancer patients without ADT or men without prostate cancer, a ... Read more

November 21, 2018

Radiation Treatments Delay Metastasis, Recurrence in Aggressive Prostate Cancers

News

Radiation therapy approaches — including external beam radiation therapy (EBRT) and brachytherapy — for prostate cancer patients with aggressive disease are better at extending the time to metastasis or ... Read more

October 26, 2018

Stereotactic Radiation Shows Ability to Significantly Extend Survival in Cancer Patients with Multiple Metastasis

News

Patients whose cancer returns at multiple sites after treatment — called oligometastatic cancer — are generally thought incurable, but a recent Phase 2 trial found that a highly precise ... Read more

October 24, 2018

Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations

News

Rubraca (rucaparib), Clovis Oncology‘s PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company ... Read more

October 18, 2018October 18, 2018

Prostate and Small Cell Cancers of the Lung Share Genetic Drivers, Study Finds

News

Small cell cancers — cancers with very poor prognosis that often develop from less-aggressive tumors as a means to evade treatment — may be driven by common mechanisms regardless ... Read more

October 15, 2018

Artificial Intelligence Could Identify Prostate Cancer Patients Likely to Relapse After Surgery, Study Reports

News

A pathology test that uses artificial intelligence could be used to examine prostate cancer samples and predict which patients are likely to relapse after surgery, a study shows. The ... Read more